Positive Results

 
News Articles for Positive Results top ^
2013/5/2
Almirall and Forest Laboratories Announce Positive Results for the Second Phase III Study for Aclidinium and Formoterol Combination in COPD Canada NewsWire BARCELONA and NEW YORK, May 2, 2013 /CNW/ - Almirall, S.A. (ALM:MC) and Forest Laboratories, Inc. (NYSE:FRX) today announced positive topline results from AUGMENT/COPD, the second six-month pivotal phase III clinical trial evaluating the efficacy and safety of investigational fixed dose combinations of aclidinium bromide (LAMA) and formoterol fumarate (LABA) for the treatment of Chronic Obstructive Pulmonary Disease (COPD), delivered in the Pressair™inhaler (Genuair ® outside the USA). The 400/12mcg combination of aclidinium/formoterol given twice daily demonstrated statistically significant improvements in change from baseline for the co-primary endpoints of Forced Expiratory Volume (FEV1) at 1 hour post-dose versus aclidinium 400mcg (p<0.0001), and morning predose trough FEV1
Sign-up for Almirall and Forest Laboratories Announce Positive Results for the Second Phase III Study for Aclidinium and Formoterol Combination in COPD investment picks
2013/4/16
Almirall and Forest Laboratories Announce Positive Results of a Phase III Study for Aclidinium and Formoterol Combination in COPD Canada NewsWire BARCELONA AND NEW YORK, April 16, 2013 /CNW/ - Almirall, S.A. (ALM:MC) and Forest Laboratories, Inc. (NYSE:FRX) today announced positive topline results from a six month pivotal phase III clinical trial evaluating the efficacy and safety of fixed dose combinations of aclidinium bromide (LAMA) and formoterol fumarate (LABA) delivered by Almirall's inhaler Genuair ®  (Pressair™ in the USA). Both combinations of aclidinium/formoterol (400/6mcg and 400/12mcg twice a day) demonstrated statistically significant improvements in the co-primary endpoints of change from baseline in morning predose trough FEV1 versus formoterol 12mcg and in FEV1 at 1 hour post-dose versus aclidinium 400mcg both at week 24 (p<0.01 and p≤0.0001, respectively). In addition, both combinations of aclidinium/formoterol
Sign-up for Almirall and Forest Laboratories Announce Positive Results of a Phase III Study for Aclidinium and Formoterol Combination in COPD investment picks
2013/5/1
Forest Laboratories, Inc. (NYSE:FRX) and Almirall, S.A. (ALM:MC) today announced positive topline results from AUGMENT COPD, the second six-month pivotal phase III clinical trial evaluating the efficacy and safety of investigational fixed dose combinations of aclidinium bromide (LAMA) and formoterol fumarate (LABA), delivered in the Pressair ® (Genuair ® outside the USA) inhaler.
Sign-up for Forest Laboratories and Almirall Announce Positive Results for the Second Phase III Study for Aclidinium and Formoterol combination in COPD investment picks
2013/4/16
Eli Lilly & Co.
Sign-up for Lilly's Diabetes Dulaglutide Treatment Shows Positive Results in Additional Phase III Trials investment picks
2013/3/13
Findings suggest value of Oncotype DX in tailoring radiation therapy treatment for select node-positive patients treated with hormonal therapy and chemotherapy Oncotype DX DCIS validation study accepted by peer-reviewed journal for publication in coming months REDWOOD CITY, Calif.
Sign-up for Genomic Health Announces Positive Results from Large Study of Oncotype DX® to Quantify Risk of Loco-Regional Recurrence in Node-positive Breast Cancer Patients and Acceptance of Oncotype DX DCIS Validation Study for Publication investment picks
2013/4/17
Medicago and IDRI Reports Positive Results for its Phase I Clinical Trial for an H5N1 Vaccine Canada NewsWire - All three configurations of adjuvant and route of administration exceeded the three CHMP criteria- QUEBEC CITY, and SEATTLE , WA, April 17, 2013 /CNW Telbec/ - Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs) and The Infectious Disease Research Institute (IDRI), a Seattle-based non-profit research organization that is a leading developer of adjuvants used in vaccines combating infectious disease, today reported positive interim results from a Phase I clinical trial for an H5N1 Avian Influenza VLP vaccine candidate ("H5N1 vaccine"). The results were announced at the World Vaccine Congress in Washington, DC .
Sign-up for Medicago and IDRI Reports Positive Results for its Phase I Clinical Trial for an H5N1 Vaccine investment picks
2013/3/21
Anacor Pharmaceuticals (NASDAQ:ANAC) today announced positive results from a Phase 2 dose-ranging trial (AN2728-AD-204) of its topical boron-based phosphodiesterase-4 (PDE-4) inhibitor, AN2728.
Sign-up for Anacor Pharmaceuticals Announces Positive Results From Phase 2 Dose-Ranging Study of AN2728 in Adolescents With Atopic Dermatitis investment picks
2013/4/17
Alkermes plc (NASDAQ: ALKS) today announced positive preliminary topline results from a phase 2 study of ALKS 5461, its novel drug compound for major depressive disorder (MDD) in patients who have an inadequate response to standard therapies for clinical depression.
Sign-up for Alkermes Announces Positive Results from Phase 2 Clinical Study of ALKS 5461 for Major Depressive Disorder investment picks
2013/2/28
Anacor Pharmaceuticals (NASDAQ:ANAC) today announced positive preliminary results from the second of two Phase 3 trials of tavaborole (known as Study 302). Tavaborole is a topical anti-fungal for the treatment of onychomycosis, a fungal infection of the nail and nail bed that affects approximately 35 million people in the United States.
Sign-up for Anacor Pharmaceuticals Announces Positive Results from the Second Phase 3 Trial of Tavaborole for Onychomycosis investment picks
2013/4/17
- All three configurations of adjuvant and route of administration exceeded the three CHMP criteria- QUEBEC CITY, and SEATTLE, WA , April 17, 2013 /PRNewswire/ - Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs) and The Infectious Disease Research Institute (IDRI), a Seattle -based non-profit research organization that is a leading developer of adjuvants used in vaccines combating infectious disease, today reported positive interim results from a Phase I clinical trial for an H5N1 Avian Influenza VLP vaccine candidate ("H5N1 vaccine"). The results were announced at the World Vaccine Congress in Washington, DC .
Sign-up for Medicago and IDRI Reports Positive Results for its Phase I Clinical Trial for an H5N1 Vaccine investment picks
2013/4/16
Company Shares Top-line Results on Two Additional AWARD Trials, Both of which Examined Efficacy Compared to Insulin Glargine INDIANAPOLIS , April 16, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive top-line results of two additional Phase III AWARD  trials for dulaglutide, an investigational, long-acting glucagon-like peptide 1 (GLP-1) receptor agonist being studied as a once-weekly treatment for type 2 diabetes.
Sign-up for Lilly Announces Positive Results of Phase III Trials of Dulaglutide in Type 2 Diabetes investment picks
2013/5/17
French pharmaceutical giant Sanofi SA (SAN.FR) Friday announced a pivotal study examining JAK2 inhibitor SAR302503 for myelofibrosis (MF) had positive results.
Sign-up for Sanofi Reports Positive Results on Study on Inhibitor in Myelofibrosis investment picks
2013/2/14
EMC Metals Corp.
Sign-up for EMC Announces Positive Results of 2012 Norway Exploration Program investment picks
2013/3/25
Tedizolid Met All Primary and Secondary Efficacy Outcomes Designated by the FDA and EMA SAN DIEGO, March 25, 2013 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) today announced top-line results from its ESTABLISH 2 Phase 3 clinical trial of tedizolid phosphate (TR-701) for the treatment of acute bacterial skin and skin structure infections (ABSSSI), including methicillin resistant Staphylococcus aureus (MRSA). As in the ESTABLISH 1 study, which tested the oral dosage form of tedizolid, the ESTABLISH 2 intravenous (IV) to oral transition study captured the endpoints for ABSSSI established by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Trius conducted the trial at 95 sites in North and South America, Europe, Australia, New Zealand and South Africa.
Sign-up for Trius Announces Positive Results From ESTABLISH 2 Study of Tedizolid in Severe Skin Infections investment picks

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Morningstar Investing Classroom Rewards (earn as you learn and redeem for Morningstar merchandise)
P   Morningstar Fund Analyst Reports (full research on 2,000 funds and ETFs)
P   Morningstar Stock Analyst Reports (full research on 2,000 stocks)
P   Morningstar Stock and Fund Stewardship Grades
P   Portfolio Manager (advanced with 10 x-ray analyses, including guidance)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Positive Results
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Positive Rate  |  Next: Positive Trends